Shire: Playing Defense While Waiting on Baxalta

Shire is buying U.S. biotech Dyax, a pricey deal that comes with plenty of risks. But it still looks pretty straight-forward against the backdrop of its big, hostile pursuit of Baxalta.

from WSJ.com: US Business http://ift.tt/1Wum1kX
via IFTTT